Cited by 1,758Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Alzheimer Mechanisms and Therapeutic Strategies

Open access
Huang, Yadong, Mucke, Lennart·2012·Cell

Abstract

There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease, but research advances over the past three decades could change this gloomy picture. Genetic studies demonstrate that the disease has multiple causes. Interdisciplinary approaches combining biochemistry, molecular and cell biology, and transgenic modeling have revealed some of its molecular mechanisms. Progress in chemistry, radiology, and systems biology is beginning to provide useful biomarkers, and the emergence of personalized medicine is poised to transform pharmaceutical development and clinical trials. However, investigative and drug development efforts should be diversified to fully address the multifactoriality of the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2012.02.040

Cites

209 of 209 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The single amino acid difference increases apoE4 cleavage by a stress-induced neuron-specific protease.

    “increases its cleavage by a stress-induced neuron-specific protease [7, 12, 16]”

    From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [7]

    In the ApoE4 section (page unavailable), the paper says apoE isoforms differ by single amino acid substitutions and neuronal apoE4 is more susceptible to cleavage than apoE3. It says stress or injury induces neuronal apoE expression, not that the protease is stress-induced; it reports cleavage in neurons but does not establish that the protease itself is neuron-specific. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Cell-specific toxicity is the result of neuron-specific apoE4 proteolysis.

    “Cell-specific toxicity is the result of neuron-specific apoE4 proteolysis [7, 12].”

    From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [7]

    In the ApoE4 section, the paper says apoE4 proteolysis generates neurotoxic fragments in neurons but not astrocytes. It calls this “one potential mechanism” for the cell-source-dependent effects, so the claim overstates the certainty of the causal link. No page number is supplied in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • ApoE4 fragments are proposed to promote neuronal dysfunction, neurodegeneration and astrogliosis.

    “in general, ApoE4 fragments are proposed to promote neuronal dysfunction, neurodegeneration and astrogliosis [11]”

    From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [11]

    The ApoE4 section states that proteolytic apoE4 fragments lead to neuronal dysfunction and degeneration. It does not link those fragments to astrogliosis; its discussion of astrocytes concerns their production of apoE and other effects. The astrogliosis part of the claim is therefore unsupported by our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Collagenase, MMP-9, neuron-specific α-chymotrypsin-like serine protease, cathepsin D and HtrA1 are proteases able to cleave ApoE4 into neurotoxic fragments.

    “Nevertheless, as previously mentioned in this review, some authors identified collagenase, MMP-9, neuron-specific α-chymotrypsin-like serine protease, cathepsin D and HtrA1 as some of the proteases that are able to cleave ApoE4 into neurotoxic fragments.”

    From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [11]

    The ApoE4 section reports that proteolytic cleavage of neuronal apoE4 produces neurotoxic fragments. However, the paper does not identify collagenase, MMP-9, neuron-specific α-chymotrypsin-like serine protease, cathepsin D, or HtrA1 as the enzymes responsible. The “Targeting ApoE4” section instead proposes identifying the protease that cleaves apoE4. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Current targeted therapeutic strategies have failed to slow cognitive decline in AD.

    “Current targeted therapeutic strategies have failed to slow down cognitive decline in AD (Graham et al., 2017; Huang and Mucke, 2012), raising concerns about these hypotheses and calling for a broad understanding of molecular and cellular components in AD brain, at both asymptomatic and symptomatic stages during the disease progression (De Strooper and Karran, 2016).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 211 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Huang, Y., & Mucke, L.
Affiliations
Gladstone Institutes (US)
Corresponding author
Mucke, Lennart
Venue
Cell
Publisher
Elsevier BV
Published
2012-03
Volume
148
Issue
6
Pages
1204-1222
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2002181764
Cited by
1,758
References
211
Citations by year
2026: 37 · 2025: 80 · 2024: 78 · 2023: 104 · 2022: 113 · 2021: 127 · 2020: 148 · 2019: 149 · 2018: 160 · 2017: 149 · 2016: 168 · 2015: 143 · 2014: 135 · 2013: 127 · 2012: 39
FWCI
15.31
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Aging (AG011385, AG022074, P01AG022074)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, disease mechanisms, treatment options, genetic risk factors, transgenic animal models, biomarkers, personalized medicine, drug development, complex diseases
MeSH terms
Alzheimer Disease, Animals, Cognition, gamma-Aminobutyric Acid, Humans, Amyloid beta-Protein Precursor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review